Davis, S. M., Deloria-Knoll, M., Kassa, H. T. & O’Brien, K. L. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32, 133–145 (2013).
Demczuk, W. H. B. et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016. Vaccine 36, 4701–4707 (2018).
Izurieta, P., Bahety, P., Adegbola, R., Clarke, C. & Hoet, B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev. Vaccines 17, 479–493 (2018).
Moore, M. R. et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect. Dis. 15, 301–309 (2015).
Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114–1125 (2015).
Falkenhorst, G. et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PloS One 12, e0169368 (2017).
Moberley, S., Holden, J., Tatham, D. P. & Andrews, R. M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 23, CD000422 (2013).
Niederman, M. S. et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev. Vaccines 20, 243–256 (2021).
Sari, R. F., Fadilah, F., Maladan, Y., Sarassari, R. & Safari, D. A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of Streptococcus pneumoniae capsular polysaccharide. Clin. Exp. Vaccin. Res 13, 91–104 (2024).
Feemster, K. H. et al. U.K. Implications of cross-reactivity and cross-protection for pneumococcal vaccine development. Vaccines 12, 974 (2024).
Cooper, D. et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 29, 7207–7211 (2011).
Grant, L. R. et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PloS One 8, e74906 (2013).
Kim, H. W., Lee, S. & Kim, K. H. Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D. Medicine 95, e4854 (2016).
Shi, Y. et al. The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C. Hum. Vaccin. Immunother. 19, 2235238 (2023).
Rinta-Kokko, H. et al. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine 38, 1559–1564 (2020).
Lee, H., Nahm, M. H., Burton, R. & Kim, K. H. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin. Vaccine Immunol. 16, 376–381 (2009).
Yeh, S. H. et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 126, e493–e505 (2010).
Platt, H. L. et al. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. Lancet Infect. Dis. 24, 1141–1150 (2024).
Jotterand, V. et al. A phase 3 randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal vaccine, compared with PPSV23, in adults >/=50 years of age (STRIDE-10). Vaccines 13, 341 (2025).
Scott, P. et al. A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (STRIDE-6). Clin. Infect. Dis. 79, 1366–1374 (2024).
Nolan, K. M. et al. Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis 12, 1003–1020 (2020).
Nolan, K. M. et al. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis 12, 1363–1375 (2020).
Antonello, J. M. et al. Establishing a new human pneumococcal standard reference serum, MPRSS-01. mSphere 10, e0040424 (2025).
Clopper, C. J. & Pearson, E. S. The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika 26, 404–413 (1934).
Ahmed, S. S. et al. Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States. Clin. Infect. Dis. 70, 2484–2492 (2020).
Andrews, N. et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine 37, 4491–4498 (2019).
Hanquet, G. et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 29, 2856–2864 (2011).
Savulescu, C. et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir. Med 5, 648–656 (2017).
Spencer, B. L., Shenoy, A. T., Orihuela, C. J. & Nahm, M. H. The pneumococcal serotype 15C capsule is partially O-acetylated and allows for limited evasion of 23-valent pneumococcal polysaccharide vaccine-elicited anti-serotype 15B antibodies. Clin. Vaccine Immunol. 24, e00099–17 (2017).
Rajam, G., Carlone, G. M. & Romero-Steiner, S. Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C. Clin. Vaccine Immunol. 14, 1223–1227 (2007).
Park, I. H. et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J. Infect. Dis. 198, 1818–1822 (2008).
Park, I. H., Park, S., Hollingshead, S. K. & Nahm, M. H. Genetic basis for the new pneumococcal serotype. 6C. Infect. Immun. 75, 4482–4489 (2007).
Haranaka, M. et al. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: a phase 1 study. Hum. Vaccin. Immunother. 19, 2228162 (2023).
Platt, H. et al. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect. Dis. 23, 233–246 (2023).
Centers for Disease Control and Prevention. Current epidemiology of pneumococcal disease among adults, United States. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-Pneumococcal-Gierke-508.pdf. Accessed August 26, 2025. (2024).
